NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-06-15	0.8970 €	-0.33%	6,201
26-06-12	0.9000 €	+1.01%	10,956
26-06-11	0.8910 €	-1.00%	12,010
26-06-10	0.9000 €	-3.12%	36,825
26-06-09	0.9290 €	-1.69%	18,769

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Real-time Euronext Paris Other stock markets 07:04:13 2026-06-15 EDT			5-day change	1st Jan Change
0.8970 ^EUR	-0.33%		-5.08%	-23.85%

06-01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
06-01	NFL Biosciences validates breakthrough in personalized medicine

Market Cap	11.41M 13.2M 10.51M 9.84M 18.44M 1.26B 18.72M 124M 48.38M 611M 49.56M 48.5M 2.12B	P/E Ratio 2024	-9.56x	P/E Ratio 2025	-4.62x
Enterprise Value	9.79M 11.33M 9.02M 8.44M 15.82M 1.08B 16.06M 106M 41.51M 524M 42.52M 41.62M 1.81B	EV / Sales 2024	370,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

06-01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
06-01	NFL Biosciences validates breakthrough in personalized medicine
05-26	Glimmers of hope for Middle East peace grow brighter
05-26	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
05-25	NFL Biosciences files new patent application
05-25	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
05-11	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
05-04	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI
04-15	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	NFL Biosciences SA announced that it expects to receive ?2.6 million in funding from Vester Finance	CI
04-13	Weekly Earnings Calendar: JPMorgan and Netflix in the US, LVMH and ASML in Europe,
03-12	JCDecaux, Maurel & Prom, Voltalia... stocks to watch today in Paris
03-11	NFL BIOSCIENCES Secures EUR 500,000 Loan from Bpifrance	CI

25-10-20	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
24-10-02	NFL Biosciences: Invest Securities reduces its target
24-07-15	NFL Biosciences: Invest Securities raises its target

NFL Biosciences Stock

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Valuation: NFL Biosciences

Chart: NFL Biosciences

Latest news : NFL Biosciences

Analysts' recommendations: NFL Biosciences

Press Releases: NFL Biosciences

News in other languages: NFL Biosciences

Quotes and Performance

Course Extremes

Managers and Directors: NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-13	Agenda des dividendes et des AG France : GTT, Alten et Exail sur les tablettes
06-02	Bourse : STMicro embrasse l'IA, BNP conteste un jugement et HPE on fire
06-02	L'IA avale (toujours) tout
06-01	NFL Biosciences valide une avancée en médecine personnalisée
06-01	NFL Biosciences : Assemblée générale mixte du 17 juin 2026 : modalités de mise à disposition et consultation des documents préparatoires

1 day	-0.33%
1 week	-5.08%
Current month	-12.57%
1 month	+1.93%
3 months	-16.17%
6 months	-13.75%
Current year	-23.85%

1 week	0.89	0.93
1 month	0.86	1.15
Current year	0.84	1.85
1 year	0.84	1.85
3 years	0.84	3.31
5 years	0.55	5
10 years	0.55	5

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	2024-10-16
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	2023-02-26
Bruno Lafont CHM	Chairman	-	2024-10-16
Francis Ahner BRD	Director/Board Member	-	2021-05-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	-0.33%	-5.08%	-23.07%	-71.52%	13.2M
ARGENX SE	-1.53%	+1.13%	+59.76%	+113.91%	56.42B
WUXI APPTEC CO., LTD.	+2.72%	+3.26%	+46.05%	+47.37%	44.54B
BIONTECH SE	+1.12%	+2.79%	-15.04%	-18.40%	22.9B
INSMED INCORPORATED	+1.17%	+3.85%	-0.89%	+407.26%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	-0.51%	+1.78%	+16.68%	-34.63%	16.4B
GENMAB A/S	0.00%	+0.25%	+9.53%	-38.48%	15.4B
EXELIXIS, INC.	-0.69%	+0.82%	+27.75%	+182.91%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.96%	+9.74%	+17.55%	-	12.36B
PHARMAESSENTIA CORPORATION	+1.61%	+1.28%	+95.75%	+206.59%	11.15B
Average	+0.45%	+1.36%	+23.41%	+88.33%	21.37B
Weighted average by Cap.	+0.46%	+2.37%	+33.38%	+101.00%

	2024	2025
Net sales	46 53.26 42.39 39.68 74.36 5.06K 75.51 500.52 195.15 2.46K 199.88 195.63 8.53K	188 217.67 173.24 162.16 303.9 20.69K 308.61 2.05K 797.56 10.07K 816.91 799.52 34.87K
Net income	-2.08M -2.41M -1.92M -1.79M -3.36M -229M -3.42M -22.64M -8.83M -111M -9.04M -8.85M -386M	-3.32M -3.84M -3.06M -2.86M -5.36M -365M -5.45M -36.1M -14.08M -178M -14.42M -14.11M -615M
Net Debt	-2.07M -2.4M -1.91M -1.79M -3.35M -228M -3.4M -22.55M -8.79M -111M -9.01M -8.81M -384M	-1.62M -1.87M -1.49M -1.4M -2.62M -178M -2.66M -17.62M -6.87M -86.75M -7.04M -6.89M -300M